Chimeric antigen receptor (CAR) T cell therapy is offering new hope to cancer patients around the world. As commercial CAR T therapies reach more patients, and new CAR T therapies are developed and approved, optimization of the manufacturing process is critical. Here, we discuss recently published research from Metzloff and colleagues at the University of […]
Since January 22nd, 2026, Accellix is part of bioMérieux, a world leader in the field of in vitro diagnostics.
Learn more about this strategic acquisition.
Publication News
Accelerating CAR T Cell Production: Researchers at UPenn Develop Novel Lipid Nanoparticle for T Cell Activation and CAR Gene Delivery
October 24, 2024 | 8 min read
